140 related articles for article (PubMed ID: 34503204)
1. TCR Clonality and Genomic Instability Signatures as Prognostic Biomarkers in High Grade Serous Ovarian Cancer.
Lecuelle J; Boidot R; Mananet H; Derangère V; Albuisson J; Goussot V; Arnould L; Tharin Z; Ray Coquard I; Ghiringhelli F; Truntzer C; Fumet JD
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503204
[TBL] [Abstract][Full Text] [Related]
2. Lymphocytic infiltration in stage II microsatellite stable colorectal tumors: A retrospective prognosis biomarker analysis.
Sanz-Pamplona R; Melas M; Maoz A; Schmit SL; Rennert H; Lejbkowicz F; Greenson JK; Sanjuan X; Lopez-Zambrano M; Alonso MH; Qu C; McDonnell KJ; Idos GE; Vignali M; Emerson R; Fields P; Guinó E; Santos C; Salazar R; Robins HS; Rennert G; Gruber SB; Moreno V
PLoS Med; 2020 Sep; 17(9):e1003292. PubMed ID: 32970670
[TBL] [Abstract][Full Text] [Related]
3. Genomic scar signatures associated with homologous recombination deficiency predict adverse clinical outcomes in patients with ovarian clear cell carcinoma.
Chao A; Lai CH; Wang TH; Jung SM; Lee YS; Chang WY; Yang LY; Ku FC; Huang HJ; Chao AS; Wang CJ; Chang TC; Wu RC
J Mol Med (Berl); 2018 Jun; 96(6):527-536. PubMed ID: 29725737
[TBL] [Abstract][Full Text] [Related]
4. T-Cell Infiltration and Clonality May Identify Distinct Survival Groups in Colorectal Cancer: Development and Validation of a Prognostic Model Based on The Cancer Genome Atlas (TCGA) and Clinical Proteomic Tumor Analysis Consortium (CPTAC).
Campana LG; Mansoor W; Hill J; Macutkiewicz C; Curran F; Donnelly D; Hornung B; Charleston P; Bristow R; Lord GM; Valpione S
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497365
[TBL] [Abstract][Full Text] [Related]
5. Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial.
Fumet JD; Lardenois E; Ray-Coquard I; Harter P; Joly F; Canzler U; Truntzer C; Tredan O; Liebrich C; Lortholary A; Pissaloux D; Leary A; Pfisterer J; Eeckhoutte A; Hilpert F; Fabbro M; Caux C; Alexandre J; Houlier A; Sehouli J; Sohier E; Kimmig R; Dubois B; Spaeth D; Treilleux I; Frenel JS; Herwig U; Le Saux O; Bendriss-Vermare N; du Bois A
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267497
[TBL] [Abstract][Full Text] [Related]
6. Dynamically Accumulating Homologous Recombination Deficiency Score Served as an Important Prognosis Factor in High-Grade Serous Ovarian Cancer.
Su R; Liu Y; Wu X; Xiang J; Xi X
Front Mol Biosci; 2021; 8():762741. PubMed ID: 34869593
[No Abstract] [Full Text] [Related]
7. T-Cell Receptor Repertoire Characteristics Associated with Prognostic Significance in High-Grade Serous Ovarian Carcinoma.
Kim JW; Kim S; Yang SY; Joung JG; Hwang S
Genes (Basel); 2023 Mar; 14(4):. PubMed ID: 37107543
[TBL] [Abstract][Full Text] [Related]
8. Inferring Homologous Recombination Deficiency of Ovarian Cancer From the Landscape of Copy Number Variation at Subchromosomal and Genetic Resolutions.
Zhang M; Ma SC; Tan JL; Wang J; Bai X; Dong ZY; Zhang QX
Front Oncol; 2021; 11():772604. PubMed ID: 34976815
[TBL] [Abstract][Full Text] [Related]
9. Identification of CXCL13 as a Promising Biomarker for Immune Checkpoint Blockade Therapy and PARP Inhibitor Therapy in Ovarian Cancer.
Ding Y; Ye Z; Ding B; Feng S; Zhang Y; Shen Y
Mol Biotechnol; 2024 Jun; ():. PubMed ID: 38856873
[TBL] [Abstract][Full Text] [Related]
10. A BRCA1/2 Mutational Signature and Survival in Ovarian High-Grade Serous Carcinoma.
Dong F; Davineni PK; Howitt BE; Beck AH
Cancer Epidemiol Biomarkers Prev; 2016 Nov; 25(11):1511-1516. PubMed ID: 27496093
[TBL] [Abstract][Full Text] [Related]
11. An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
Przybytkowski E; Davis T; Hosny A; Eismann J; Matulonis UA; Wulf GM; Nabavi S
BMC Cancer; 2020 Mar; 20(1):197. PubMed ID: 32164626
[TBL] [Abstract][Full Text] [Related]
12. Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas.
Li H; Tu J; Zhao Z; Chen L; Qu Y; Li H; Yao H; Wang X; Lee DF; Shen J; Wen L; Huang G; Xie X
Theranostics; 2020; 10(21):9477-9494. PubMed ID: 32863940
[No Abstract] [Full Text] [Related]
13. Pan-cancer analysis reveals homologous recombination deficiency score as a predictive marker for immunotherapy responders.
Yang C; Zhang Z; Tang X; Zhang X; Chen Y; Hu T; Zhang H; Guan M; Zhang X; Wu Z
Hum Cell; 2022 Jan; 35(1):199-213. PubMed ID: 34628623
[TBL] [Abstract][Full Text] [Related]
14. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
15. Homologous Recombination Repair Mechanisms in Serous Endometrial Cancer.
Jönsson JM; Bååth M; Björnheden I; Sahin ID; Måsbäck A; Hedenfalk I
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33445465
[TBL] [Abstract][Full Text] [Related]
16. Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression.
Ashley CW; Da Cruz Paula A; Kumar R; Mandelker D; Pei X; Riaz N; Reis-Filho JS; Weigelt B
Gynecol Oncol; 2019 Jan; 152(1):11-19. PubMed ID: 30415991
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of T-Cell Receptor Repertoire and Correlation With
Yang H; Wang Y; Jia Z; Wang Y; Yang X; Wu P; Song Y; Xu H; Gu D; Chen R; Xia X; Bing Z; Gao C; Cao L; Li S; Cao Z; Liang N
Front Oncol; 2021; 11():537735. PubMed ID: 33777727
[TBL] [Abstract][Full Text] [Related]
18. CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy.
Komdeur FL; Wouters MC; Workel HH; Tijans AM; Terwindt AL; Brunekreeft KL; Plat A; Klip HG; Eggink FA; Leffers N; Helfrich W; Samplonius DF; Bremer E; Wisman GB; Daemen T; Duiker EW; Hollema H; Nijman HW; de Bruyn M
Oncotarget; 2016 Nov; 7(46):75130-75144. PubMed ID: 27650547
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma.
Chen H; Molberg K; Strickland AL; Castrillon DH; Carrick K; Jiang Q; Niu S; Rivera-Colon G; Gwin K; Hinson S; Lea J; Miller DS; Zheng W; Lucas E
Am J Surg Pathol; 2020 Aug; 44(8):1050-1060. PubMed ID: 32384321
[TBL] [Abstract][Full Text] [Related]
20. A transcriptional signature detects homologous recombination deficiency in pancreatic cancer at the individual level.
Zhuang S; Chen T; Li Y; Wang Y; Ai L; Geng Y; Zou M; Liu K; Xu H; Wang L; Zhao Z; Chang Z; Gu Y
Mol Ther Nucleic Acids; 2021 Dec; 26():1014-1026. PubMed ID: 34786207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
